JP2019532105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532105A5 JP2019532105A5 JP2019541893A JP2019541893A JP2019532105A5 JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5 JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- dry eye
- severe dry
- surgery
- treating severe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 claims 30
- 206010013774 Dry eye Diseases 0.000 claims 15
- 230000002335 preservative Effects 0.000 claims 15
- 239000003755 preservative agent Substances 0.000 claims 15
- 238000001356 surgical procedure Methods 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000000975 bioactive Effects 0.000 claims 6
- 239000003599 detergent Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 210000000170 Cell Membrane Anatomy 0.000 claims 3
- 206010022114 Injury Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000002209 hydrophobic Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229920002413 Polyhexanide Polymers 0.000 claims 2
- 230000001580 bacterial Effects 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 230000001590 oxidative Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 1
- 229960004926 Chlorobutanol Drugs 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- 206010072736 Rheumatic disease Diseases 0.000 claims 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 229940075582 Sorbic Acid Drugs 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 230000002009 allergen Effects 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 230000003139 buffering Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 229940009662 edetate Drugs 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000000813 microbial Effects 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 230000003204 osmotic Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 125000005430 oxychloro group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 230000002269 spontaneous Effects 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122165A JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408559P | 2016-10-14 | 2016-10-14 | |
| US62/408,559 | 2016-10-14 | ||
| US201762516911P | 2017-06-08 | 2017-06-08 | |
| US62/516,911 | 2017-06-08 | ||
| PCT/IB2017/001364 WO2018069763A1 (en) | 2016-10-14 | 2017-10-02 | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Division JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532105A JP2019532105A (ja) | 2019-11-07 |
| JP2019532105A5 true JP2019532105A5 (ru) | 2020-11-12 |
Family
ID=60766004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541893A Pending JP2019532105A (ja) | 2016-10-14 | 2017-10-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190240251A1 (ru) |
| EP (2) | EP3871682A1 (ru) |
| JP (2) | JP2019532105A (ru) |
| KR (1) | KR20190068575A (ru) |
| ES (1) | ES2909998T3 (ru) |
| HU (1) | HUE058672T2 (ru) |
| PL (1) | PL3525799T3 (ru) |
| WO (1) | WO2018069763A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190068575A (ko) | 2016-10-14 | 2019-06-18 | 이콤 메디칼 게엠베하 | 안구 표면 항상성의 확립, 회복 및 보존 방법 |
| EP3781175A1 (en) * | 2018-04-18 | 2021-02-24 | i.com Medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| CN112714644B (zh) * | 2018-09-20 | 2024-03-29 | 香港科技大学 | 滴眼剂组合物 |
| US20210369764A1 (en) * | 2019-01-31 | 2021-12-02 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| EP4106772A1 (en) * | 2020-06-12 | 2022-12-28 | i.com Medical GmbH | High molecular weight hyaluronic acid for use in the treatment of corneal nerve damage or loss |
| US20230338541A1 (en) * | 2020-06-21 | 2023-10-26 | i.com medical GmbH | Use of high molecular weight hyaluronic acid as ocular transporting vehicle |
| WO2023240155A1 (en) * | 2022-06-08 | 2023-12-14 | The Schepens Eye Research Institute, Inc. | Methods for treating dry eye disease |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1263606A (en) * | 1985-05-29 | 1989-12-05 | Jeffrey P. Gilbard | Non-toxic opthalmic preparations |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| JP3050898B2 (ja) * | 1990-07-06 | 2000-06-12 | 千寿製薬株式会社 | 水性医薬製剤 |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| IT1277707B1 (it) * | 1995-12-22 | 1997-11-11 | Chemedica Sa | Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare |
| SE9700827D0 (sv) * | 1997-03-07 | 1997-03-07 | Pharmacia & Upjohn Ab | Ophthalmic composition |
| EP1142566B1 (fr) * | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| US6528464B1 (en) * | 2001-08-17 | 2003-03-04 | Bausch & Lomb Incorporated | Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels |
| JP3779200B2 (ja) * | 2001-11-28 | 2006-05-24 | 電気化学工業株式会社 | ヒアルロン酸及び／又はその塩の水溶液の安定化組成物 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| CN103638040A (zh) * | 2002-07-03 | 2014-03-19 | 派瑞克科学公司 | 透明质酸组合物以及使用方法 |
| DE10360425A1 (de) | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung |
| WO2007043702A1 (en) * | 2005-10-12 | 2007-04-19 | Seikagaku Corporation | Agent for applying to mucosa and method for production thereof |
| JP2008255061A (ja) * | 2007-04-06 | 2008-10-23 | Shiseido Co Ltd | 可溶性架橋ヒアルロン酸含有眼用組成物 |
| EP2187900B1 (en) * | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| US20110065642A1 (en) * | 2008-05-15 | 2011-03-17 | R-Tech Ueno, Ltd. | Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion |
| JP5595206B2 (ja) * | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| US8283463B2 (en) * | 2010-02-09 | 2012-10-09 | Bausch & Lomb Incorporated | Sterile hyaluronic acid solutions |
| CN103221422B (zh) * | 2010-07-29 | 2017-03-29 | 十一生物治疗股份有限公司 | 嵌合il‑1受体i型激动剂和拮抗剂 |
| AU2011299851A1 (en) * | 2010-09-10 | 2013-04-04 | Santen Pharmaceutical Co., Ltd. | Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof |
| EP3226853B1 (en) * | 2014-12-02 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Animal model for dry eye and methods of use of such animals |
| JP6716293B2 (ja) * | 2015-03-06 | 2020-07-01 | 参天製薬株式会社 | 眼科用組成物 |
| US20170014339A1 (en) | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
| KR20190068575A (ko) | 2016-10-14 | 2019-06-18 | 이콤 메디칼 게엠베하 | 안구 표면 항상성의 확립, 회복 및 보존 방법 |
-
2017
- 2017-10-02 KR KR1020197013278A patent/KR20190068575A/ko not_active IP Right Cessation
- 2017-10-02 EP EP21167346.2A patent/EP3871682A1/en active Pending
- 2017-10-02 EP EP17817868.7A patent/EP3525799B1/en active Active
- 2017-10-02 WO PCT/IB2017/001364 patent/WO2018069763A1/en active Search and Examination
- 2017-10-02 PL PL17817868T patent/PL3525799T3/pl unknown
- 2017-10-02 US US16/341,915 patent/US20190240251A1/en active Pending
- 2017-10-02 ES ES17817868T patent/ES2909998T3/es active Active
- 2017-10-02 HU HUE17817868A patent/HUE058672T2/hu unknown
- 2017-10-02 JP JP2019541893A patent/JP2019532105A/ja active Pending
-
2022
- 2022-07-29 JP JP2022122165A patent/JP2022153583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532105A5 (ru) | ||
| US20210401789A1 (en) | Ophthalmic compositions and methods for treating eyes | |
| CN111991415B (zh) | 一种眼部护理组合物及其制备方法和用途 | |
| CN101312711B (zh) | 不含右泛醇、钙离子和磷酸盐的药物组合物以及钙螯合剂和眼科相容粘度调节剂的应用 | |
| US20070141091A1 (en) | Biguanide ointment and method of treatment and prevention of infections | |
| CN103037858A (zh) | 用于预防和治疗接触镜致乳头性结膜炎以及过敏性眼病的组合物 | |
| US7820639B2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| WO2021101883A1 (en) | Chitosan containing compositions and methods relating to same | |
| KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
| JP2008189677A (ja) | 洗浄剤 | |
| WO2020140365A1 (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
| US9233123B1 (en) | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan | |
| US20190151352A1 (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| JP5957517B2 (ja) | 結膜弛緩症治療用の点眼薬 | |
| US8551974B1 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| JP2023038930A (ja) | 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法 | |
| KR20220008720A (ko) | 카라기난을 포함하는 점안용 조성물 | |
| JP2004043516A (ja) | 眼科用剤 |